Beijing Aosaikang’s ASKB589 shows strong efficacy in gastric cancer trial

ASKGENE LIMITED, a subsidiary of Beijing Aosaikang Pharmaceutical, will unveil updated efficacy data from its Ib/II clinical study of ASKB589. The drug is used in combination with CAPOX and a PD-1 inhibitor for first-line treatment of advanced gastric and gastroesophageal junction adenocarcinoma. The data will be presented as a poster at the 2025 ESMO annual meeting in Berlin, Germany, on October 19, 2025.

The Ib/II study enrolled 62 CLDN18.2-positive G/GEJ adenocarcinoma patients. For IV stage G/GEJ adenocarcinoma patients with high CLDN18.2 expression, the confirmed objective response rate (cORR) was 76.1%, with a median duration of response (mDOR) of 13.9 months. The disease control rate (DCR) was 100%. As of August 30, 2025, with a median follow-up of 26.71 months, the median progression-free survival (mPFS) was 12.45 months, and the median overall survival (mOS) was 21.36 months.

For IV stage G/GEJ adenocarcinoma patients with high CLDN18.2 expression, the cORR was 81.8%, mPFS was 15.01 months, and mOS was 22.34 months. These positive results support ongoing key Phase III clinical studies of ASKB589 in combination with chemotherapy and PD-1 inhibitors, enhancing the company's future market competitiveness.